Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2811 in Advanced Solid Tumours
NCT02579226Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- Feb 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of defosbarasertib in solid tumor and small cell lung cancer (SCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Dose-Limiting Toxicities, Incidence of Adverse Events and 1 more. Started Oct 2015; status: completed.
02
Drugs
defosbarasertib
03
Conditions
solid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02579226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579226.